🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Relapsed or Refractory Acute Myeloid Leukemia (AML)

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML NCT05735184Phase 144 sites📍 Phoenix📍 La Jolla📍 Los Angeles Kura Oncology, Inc. · Tests: Ziftomenib, Venetoclax, Azacitidine, Daunorubicin, Cytarabine A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS. NCT04275518Phase 114 sites📍 Beijing📍 Guangzhou📍 Guangzhou Ascentage Pharma Group Inc. · Tests: APG-115, Azacitidine, Cytarabine A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias NCT06994676Phase 111 sites📍 Duarte📍 Palo Alto📍 Tampa Crossbow Therapeutics, Inc. · Tests: CBX-250 A Long-term Follow-up Study of Patients With ARD103 CAR-T Cell Therapies NCT06906380n/a3 sites📍 Charlotte📍 Winston-Salem📍 Houston ARCE Therapeutics, Inc. · Tests: Non interventional study Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation NCT06316960Phase 212 sites📍 Hefei📍 Hefei📍 Guangzhou Children's Hospital of Soochow University · Tests: Avapritinib, Azacitidine Injection, Decitabine Injection, Idarubicin Hydrochloride, Cytarabine SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies NCT07153068Phase 1, Phase 21 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: supCD7 CART cells A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia NCT06880354Phase 11 site📍 Tianjin Institute of Hematology & Blood Diseases Hospital, China · Tests: CLL1 and CD38 Dual-Target CAR-T Cell Injection Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML/HR-MDS and in Combination With Azacitidine in Previously Untreated HR-MDS NCT06533761Phase 112 sites📍 Duarte📍 Aurora📍 Tampa Stelexis BioSciences · Tests: Eganelisib, Eganelisib in combination with cytarabine, Eganelisib in combination with azacitidine, Azacitadine (AZA) Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome NCT04047641Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Cladribine, Cytarabine, Idarubicin, Quizartinib Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome NCT03661307Phase 1, Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Decitabine, Quizartinib, Venetoclax Venetoclax Basket Trial for High Risk Hematologic Malignancies NCT05292664Phase 15 sites📍 San Francisco📍 Aurora📍 Atlanta Andrew E. Place, MD · Tests: Venetoclax, Azacitidine, Cytarabine, Methotrexate, Hydrocortisone Off-the-shelf CD123 CAR-NK for R/R AML NCT06201247EARLY Phase 11 site📍 Beijing Peking University People's Hospital · Tests: JD123 injection A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome NCT04243785Phase 13 sites📍 Duarte📍 New York📍 Houston Edgewood Oncology Inc. · Tests: BTX-A51, Azacitidine HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML NCT05586074Phase 31 site📍 Hanzhou Sunshine Lake Pharma Co., Ltd. · Tests: Clifutinib, LoDAC, Azacitidine, Decitabine, Ara-C±IDA Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML NCT07355335Phase 12 sites📍 Boston📍 Boston Massachusetts General Hospital · Tests: Ziftomenib, Mezigdomide A Study of CHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AML NCT07751991Phase 15 sites📍 Duarte📍 New Haven📍 Grand Rapids Charm Therapeutics · Tests: CHM-029 Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia NCT06816134Phase 21 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: TmBU conditioning Regimen, mBUCY conditioning regimen Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML NCT06561152Phase 1, Phase 21 site📍 Palo Alto Stanford University · Tests: Tagraxofusp, Cladribine (CLAD), Cytarabine IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia. NCT06713837Phase 351 sites📍 Brno📍 Hradec Králové📍 Olomouc Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IR… · Tests: High intensity therapies, Low intensity therapies Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies NCT07523555Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: Autologous CD19/CD22 dual-target CAR-T module, Autologous CD19/CD20 dual-target CAR-T module, Autologous BCMA/CD19 dual… Venetoclax, Chidamide, and Chiglitazar Sodium (VCC) in Patients With Relapsed/Refractory Acute Myeloid Leukemia NCT07783100Phase 21 site📍 Xiamen The First Affiliated Hospital of Xiamen University · Tests: venetoclax, chidamide, and chiglitazar sodium (VCC) CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML NCT07347418Phase 11 site📍 Aurora University of Colorado, Denver · Tests: CD64 CAR T Cells A Single-arm, Prospective Study of TBI + BUMEL As a Conditioning Regimen for Salvage HSCT in Patients with R/R AML NCT06879847NA1 site📍 Suzhou The First Affiliated Hospital of Soochow University · Tests: Salvage Allogeneic Hematopoietic Stem Cell Transplantation Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation NCT07256210Phase 21 site📍 Moscow Federal Research Institute of Pediatric Hematology, Oncolog… · Tests: Donor-derived Natural Killer Cell A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes NCT06146257Phase 18 sites📍 Duarte📍 Irvine📍 Kansas City GluBio Therapeutics Inc. · Tests: GLB-001 Master Framework For Relapse or Refractory Acute Myeloid Leukemia NCT06459024n/a41 sites📍 Aachen📍 Greifswald📍 Halle Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IR… · Tests: Registration into the STREAM platform A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM) NCT07771803EARLY Phase 11 site📍 Camden Roger Strair · Tests: Soursop tea Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL NCT04872478Phase 13 sites📍 Atlanta📍 Atlanta📍 New York Meryx, Inc. · Tests: MRX-2843 Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation NCT03683433Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Azacitidine, Enasidenib Mesylate HPB-092 for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia NCT07137637Phase 11 site📍 Tianjin Hangzhou Polymed Biopharmaceuticals, Inc. · Tests: HPB-092 tablet
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy